Epidemiologic Impact of HPV Vaccination
HPV 疫苗的流行病学影响
基本信息
- 批准号:10227738
- 负责人:
- 金额:$ 61.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-01-18 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:15 year oldAddressAdherenceAgeAnogenital cancerAreaAutomobile DrivingBehaviorBehavioral MechanismsBiologicalCervical Cancer ScreeningClinicClinicalClinical TrialsCommunitiesCost Effectiveness AnalysisCounselingDataData SetDeath RateDiagnosticDoseEffectivenessEnrollmentEpidemiological trendEpidemiologyGenotypeGoalsHealthy People 2020Human Papilloma Virus VaccinationHuman Papilloma Virus VaccineHuman Papilloma Virus-Related Malignant NeoplasmHuman PapillomavirusHuman papilloma virus infectionHuman papillomavirus 16IndividualInfectionInfrastructureInvestigationLongitudinal trendsMalignant NeoplasmsMalignant neoplasm of cervix uteriMarketingMethodologyMethodsMorbidity - disease rateMorphologic artifactsOutcomePoliciesPopulation HeterogeneityPrevalencePublic HealthPublicationsRecommendationReportingResearchRiskRisk ReductionScheduleScreening for cancerSeminalSentinel SurveillanceSignal TransductionTimeVaccinatedVaccinationVaccine Clinical TrialVaccinesWomanWorkbaseclinical practicecommunity settingdetection assaydisparity reductionethnic diversityexperiencehealth communicationhigh risk populationhuman femaleinclusion criteriainnovationmalemalignant oropharynx neoplasmmenmortalitynon-compliancenovelpreventprophylacticracial diversityrecruitscreening programsurveillance studytrendvaccine effectivenessvirologyyoung manyoung woman
项目摘要
Project Summary
Introduction of prophylactic human papillomavirus (HPV) vaccines has the potential to dramatically decrease
morbidity and mortality from anogenital and oropharyngeal cancers. However, data from vaccine clinical trials
cannot predict vaccine effectiveness in “real-world” community settings, and introduction of a 9-valent (in
addition to a 2- and 4-valent) vaccine in 2015 and reduced dosing schedules (from 3 to 2 doses) in 2016 could
further modify vaccine effectiveness. The impact of vaccine introduction can be efficiently and accurately
evaluated by HPV surveillance studies that assess vaccine effectiveness, herd protection, cross-protection
(decrease in HPV types genetically related to vaccine types), and type replacement (increase in non-vaccine-
type HPV due to a reduction in vaccine types). We previously conducted 4 HPV surveillance studies in women
(2006-2017) and 2 in men (2013-2017). Among women, we found evidence for vaccine effectiveness (but
lower effectiveness with 1 vs. 3 doses), herd protection, and cross-protection; no evidence for type-
replacement; and an unexpected increase in non-vaccine-type HPV in unvaccinated women. Among men, we
found preliminary evidence for vaccine effectiveness and herd protection. Continued investigation through the
proposed renewal is essential to achieve the following objectives: 1) assess the effects of 9-valent vaccine
introduction and reduced dosing schedules on effectiveness, 2) elucidate long-term trends in herd protection,
3) identify signals of diminished cross-protection or emerging type-replacement, and 4) determine mechanisms
for increases in non-vaccine-type HPV in unvaccinated women. The specific aims are to: 1) determine long-
term trends in 4-valent - and emerging trends in 9-valent - HPV prevalence among vaccinated women (2006-
2023) and men (2013-2023) to assess HPV vaccine effectiveness, and among unvaccinated women and men
to assess herd protection; 2) assess the differential impact of the number of vaccine doses received on
vaccine-type HPV, by age; 3) determine trends in non-vaccine-type HPV prevalence among vaccinated women
and men, to examine for persistent cross-protection and emerging type replacement; and 3) explore biological
and behavioral mechanisms for the increase in non-vaccine-type HPV in unvaccinated women. Our approach
will be to enroll 1,600 women and men in two additional surveillance studies, to characterize the impact of
vaccine introduction across a total of 6 time periods in women (2006-2023, N=2,400) and 4 in men (2013-
2023, N=1,600). The proposed research is innovative because the resulting data could shift current research
and clinical practice paradigms in the areas of vaccination and virology, and the research plan utilizes novel
concepts, approaches and new methodologies to explore mechanisms driving HPV trends. The proposed
research is significant because the data will provide key evidence for: 1) vaccination and cervical cancer
screening programs; 2) public health communications and risk-reduction counseling; and 3) cost-effectiveness
analysis and policy decisions: these will help to reduce disparities and mortality due to HPV-related cancers.
项目摘要
预防性人乳头瘤病毒(HPV)疫苗的引入有可能大大减少
肛门生殖器癌和口咽癌的发病率和死亡率。然而,疫苗临床试验的数据显示,
不能预测疫苗在“真实世界”社区环境中的有效性,以及9价疫苗的引入(在
在2015年增加2价和4价疫苗,并在2016年减少剂量方案(从3剂减少到2剂),
进一步提高疫苗的有效性。疫苗引进的影响可以有效和准确地
通过评估疫苗有效性、群体保护、交叉保护的HPV监测研究进行评估
(与疫苗类型遗传相关的HPV类型减少)和类型替代(非疫苗-
由于疫苗类型减少,HPV类型减少)。我们之前在女性中进行了4项HPV监测研究
(2006-2017年)和2名男子(2013-2017年)。在女性中,我们发现了疫苗有效性的证据(但
1剂与3剂相比有效性较低)、群体保护和交叉保护;没有证据表明
替代;以及未接种疫苗的妇女中非疫苗型HPV的意外增加。在男人中,我们
发现了疫苗有效性和牛群保护的初步证据。继续调查,
建议的更新对于实现以下目标至关重要:1)评估9价疫苗的效果
引入和减少给药方案对有效性的影响,2)阐明牛群保护的长期趋势,
3)识别交叉保护减弱或出现类型替换的信号,以及4)确定机制
在未接种疫苗的女性中,非疫苗型HPV的增加。具体目标是:(1)确定长期-
接种疫苗妇女中4价HPV流行率的长期趋势和9价HPV流行率的新趋势(2006-
2023年)和男性(2013-2023年)评估HPV疫苗的有效性,以及未接种疫苗的女性和男性
评估牛群保护; 2)评估接种疫苗次数对
按年龄分列的疫苗型HPV; 3)确定接种疫苗的妇女中非疫苗型HPV的流行趋势
和男性,检查持续的交叉保护和新兴的类型替代;和3)探索生物学
以及未接种疫苗的女性中非疫苗型HPV增加的行为机制。我们的方法
将在另外两项监测研究中招募1,600名女性和男性,
在总共6个时间段(2006-2023年,N= 2,400)和4个时间段(2013- 2016年,N= 2,400)中,女性和男性接种疫苗。
2023,N= 1,600)。这项研究具有创新性,因为由此产生的数据可能会改变目前的研究
以及疫苗接种和病毒学领域的临床实践范例,研究计划利用新的
概念,方法和新方法,探索推动HPV趋势的机制。拟议
研究是重要的,因为数据将提供关键证据:1)疫苗接种和宫颈癌
筛查计划; 2)公共卫生沟通和降低风险咨询; 3)成本效益
分析和政策决定:这将有助于减少因HPV相关癌症造成的差异和死亡率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JESSICA A KAHN其他文献
JESSICA A KAHN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JESSICA A KAHN', 18)}}的其他基金
Center for Clinical and Translational Science and Training
临床和转化科学与培训中心
- 批准号:
10613549 - 财政年份:2015
- 资助金额:
$ 61.56万 - 项目类别:
Center for Clinical and Translational Science and Training
临床和转化科学与培训中心
- 批准号:
10409663 - 财政年份:2015
- 资助金额:
$ 61.56万 - 项目类别:
Behavioral and Virologic Impact of HPV Immunization
HPV 免疫对行为和病毒学的影响
- 批准号:
7385443 - 财政年份:2008
- 资助金额:
$ 61.56万 - 项目类别:
Behavioral and Virologic Impact of HPV Immunization
HPV 免疫对行为和病毒学的影响
- 批准号:
8204950 - 财政年份:2008
- 资助金额:
$ 61.56万 - 项目类别:
相似海外基金
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 61.56万 - 项目类别:
Evaluating Centralizing Interventions to Address Low Adherence to Lung Cancer Screening Follow-up in Decentralized Settings
评估集中干预措施,以解决分散环境中肺癌筛查随访依从性低的问题
- 批准号:
10738120 - 财政年份:2023
- 资助金额:
$ 61.56万 - 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
- 批准号:
10526768 - 财政年份:2022
- 资助金额:
$ 61.56万 - 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
- 批准号:
10701072 - 财政年份:2022
- 资助金额:
$ 61.56万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10679092 - 财政年份:2021
- 资助金额:
$ 61.56万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10432133 - 财政年份:2021
- 资助金额:
$ 61.56万 - 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
- 批准号:
10327065 - 财政年份:2021
- 资助金额:
$ 61.56万 - 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
- 批准号:
10377366 - 财政年份:2019
- 资助金额:
$ 61.56万 - 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
- 批准号:
10574496 - 财政年份:2019
- 资助金额:
$ 61.56万 - 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
- 批准号:
9403567 - 财政年份:2017
- 资助金额:
$ 61.56万 - 项目类别: